Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02075515 · ClinicalTrials.gov registry record · Phase 3
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 651
- Enrollment target
NCT02075515: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT02075515 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 651 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02075515, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 651 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.
Primary Outcome
Anti-gE antibody concentrations, as determined by Enzyme-linked Immunosorbent Assay (ELISA). The cut-off value was ≥ 97 milli international units per milliliter (mIU/mL).
Interventions
- BIOLOGICAL Herpes Zoster vaccine (GSK 1437173A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 651 participants |
| Start Date | 2014-08-13 |
| Est. Completion | 2016-04-25 |
| Phase | Phase 3 |
What the finished NCT02075515 record still lists
NCT02075515 is an interventional study that assigns participants to a tested intervention. The registered 651 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower).
The record links to 0 conditions, and to 1 intervention - of which Herpes Zoster vaccine (GSK 1437173A) is the first listed.
NCT02075515 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02075515 about?
NCT02075515 is a clinical study titled "Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age". The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.
What is the current status of trial NCT02075515?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 651 participants. The study started on 2014-08-13. Estimated completion is 2016-04-25.
What interventions are being tested in trial NCT02075515?
The interventions under investigation include: Herpes Zoster vaccine (GSK 1437173A) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02075515?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02075515's enrollment target sits among peer trials
651 572nd of 2000 higher than 1,429 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06287346 · 652 participants
5-Years PMCF Study of Ceramic Dental Implants One-piece Versus Two-piece.
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI